CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Pharmacotherapy for acute respiratory infections caused by influenza viruses: Current possibilities
Authors
Zyryanov S.K.
Publication date
1 January 2021
Publisher
Abstract
Routinely the influenza virus significantly contributes to the formation of the annual incidence of acute respiratory infections, with a peak in winter season. The high level of mutagenic potential of influenza viruses is a standard factor determining the complexity of the rational choice of pharmacotherapy. The upcoming epidemiological season 2020-2021 brings additional challenges for health care practitioners mediated by the widespread prevalence in the human population of a new infection caused by the SARS-CoV-2 virus affecting the respiratory system among many organs and systems. An adequate choice of pharmacotherapy tools should be based on high efficiency and safety of drugs, with a possible reduction in such negative factors as polypharmacy. This review includes comparative pharmacological characteristics of drugs with activity against RNA viruses, along with parameters of their clinical efficacy. © 2021 Consilium Medikum. All rights reserved
Similar works
Full text
Available Versions
NEICON
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:covid19.neicon.pro:dc/1062...
Last time updated on 07/10/2021
NEICON
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:covid19.neicon.pro:dc/6601
Last time updated on 07/10/2021